Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

Press Releases

Year

February 18, 2022

Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances

Additional Formats

PDF Version

January 6, 2022

Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

Additional Formats

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 22 of 22

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2023 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter